Participated · Equity · Jun 2026

Nanordica Medical’s core product, Premotiv, is a patent-protected wound dressing designed to prevent infection while promoting healing without relying on systemic antibiotics. In a randomised controlled trial of 30 patients with diabetic foot ulcers, Premotiv demonstrated a 43% reduction in wound area after one week versus 13% with standard silver dressings, with results published in the Journal of Wound Care. The company is conducting a larger multicentre, double-blind, randomised clinical trial with more than 120 patients enrolled to generate stronger evidence for reimbursement and guideline adoption. Nanordica launched a veterinary product, Ravimus Vet, in 2023 which is distributed in six countries, and has been awarded a European patent. The company has received a €2.4 million EIC Accelerator grant to support clinical and development activities and intends to pursue CE marking for the human product prior to European launch.